Joan Lop1, Jacinto García2, Montserrat López2, Miren Taberna3, Marisa Mena4, Laia Alemany4, Miquel Quer2, Xavier León2,5. 1. Otorhinolaryngology Department, Hospital Parc Taulí, Universitat Autònonoma de Barcelona, Sabadell, Spain. 2. Otorhinolaryngology Department, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Medical Oncology Department, Catalan Institute of Oncology (ICO), Institut d'Investigació Biomédica de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain. 4. Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Institut d'Investigació Biomédica de Bellvitge, L'Hospitalet de Llobregat, Spain. 5. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
Abstract
BACKGROUND: The objective of the present study is to assess differences in the competing causes of death in patients with oropharyngeal carcinoma (OPC) as a function of the human papillomavirus (HPV) status. METHODS: We studied retrospectively 423 patients with OPC with known HPV status. Among the patients included in the study, 53 (12.5%) were HPV-positive. We analyzed overall survival and competing causes of mortality according to the HPV status of the patients. RESULTS: Patients with HPV-negative tumors had lower OPC cancer-specific survival (P = .0001), second primary neoplasm survival (P = .0001), and noncancer-related causes survival (P = .13) than patients with HPV-positive tumors. This resulted in significant differences in overall survival depending on HPV status (P = .0001). CONCLUSION: Conclusion: HPV-positive OPC has a better overall survival than HPV-negative OPC. Patients with HPV-positive tumors presented a significant lower OPC cancer-specific and second primary neoplasm mortality and a marginally nonsignificant lower noncancer mortality as compared to HPV-negative tumors.
BACKGROUND: The objective of the present study is to assess differences in the competing causes of death in patients with oropharyngeal carcinoma (OPC) as a function of the human papillomavirus (HPV) status. METHODS: We studied retrospectively 423 patients with OPC with known HPV status. Among the patients included in the study, 53 (12.5%) were HPV-positive. We analyzed overall survival and competing causes of mortality according to the HPV status of the patients. RESULTS:Patients with HPV-negative tumors had lower OPC cancer-specific survival (P = .0001), second primary neoplasm survival (P = .0001), and noncancer-related causes survival (P = .13) than patients with HPV-positive tumors. This resulted in significant differences in overall survival depending on HPV status (P = .0001). CONCLUSION: Conclusion:HPV-positive OPC has a better overall survival than HPV-negative OPC. Patients with HPV-positive tumors presented a significant lower OPC cancer-specific and second primary neoplasm mortality and a marginally nonsignificant lower noncancer mortality as compared to HPV-negative tumors.
Authors: Brian O'Sullivan; Shao Hui Huang; Thomas Keane; Wei Xu; Jie Su; John Waldron; Patrick Gullane; Fei-Fei Liu; Padraig Warde; David Payne; Li Tong; Bernard Cummings Journal: Clin Transl Radiat Oncol Date: 2020-01-28